Navigation Links
Novartis launches Arcapta™ Neohaler™, a novel once-daily bronchodilator for chronic obstructive pulmonary disease
Date:3/19/2012

reatment groups.

Indacaterol was first approved in November 2009 in the European Union under the brand-name Onbrez® Breezhaler®. It is now approved in more than 80 countries for the treatment of COPD, and is available in more than 30 countries with additional launches planned during 2012.

Important Safety InformationWARNING: ASTHMA-RELATED DEATHLong-acting beta2-adrenergic agonists (LABA) increase the risk of asthma-related death. Data from a large placebo-controlled US study that compared the safety of another long-acting beta2-adrenergic agonist (salmeterol) or placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol. This finding with salmeterol is considered a class effect of LABA, including indacaterol, the active ingredient in Arcapta Neohaler. The safety and efficacy of Arcapta Neohaler in patients with asthma have not been established. Arcapta Neohaler is not indicated for the treatment of asthma.All LABA are contraindicated in patients with asthma without use of a long-term asthma control medication.

Arcapta Neohaler should not be initiated in patients with acutely deteriorating COPD, which may be a life-threatening condition, or used as rescue therapy for acute episodes of bronchospasm. Acute symptoms should be treated with an inhaled short-acting beta2-agonist.

Arcapta Neohaler should not be used more often, at higher doses than recommended, or in conjunction with other medications containing long-acting beta2-agonists as an overdose may result. Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs.

Arcapta Neohaler may produce paradoxical bronchospasm that may be life-threatening. If paradoxical bronchospasm occurs, Arcapta Neohaler should be discontinued immediately and alternative therapy instituted.

Arcapta Neohaler can produce a clinically signific
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Data in NEJM shows Novartis drug Signifor® is first therapy to provide rapid, durable benefit for Cushings disease patients in Phase III study
2. FDA approves Novartis drug Gleevec® label recommending extending treatment to three years for certain GIST patients after surgery
3. Unity Management Group Subsidiary Announces First Contracts of 2012 with Purdue Pharma L.P. and Novartis
4. Endo Announces Potential Short-Term Supply Constraints of Certain Analgesic Medications as a Result of Temporary Shut Down of Novartis Facility
5. Novartis Consumer Health Inc. Issues Voluntary Nationwide Recall of Certain Over-the-Counter Products Due to Potential Presence of Foreign Tablets or Chipped or Broken Tablets or Gelcaps
6. Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec®
7. New Data Confirms Novartis Drug Afinitor® Significantly Extends Time Women With Advanced Breast Cancer Live Without Tumor Growth
8. Novartis Study Shows QTI571 Significantly Improved Walking Distance in Patients with Life-Threatening Pulmonary Arterial Hypertension
9. Novartis Drug Afinitor® Effective in Patients With Non-Cancerous Kidney Tumors Associated With TSC in Phase III Trial
10. Novartis Study Showed ACZ885 Provided Substantial Symptom Relief in 84% of Patients With the Most Serious Form of Childhood Arthritis
11. Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... Texas , Sept. 4, 2015  Luminex Corporation ... present at the Morgan Stanley Global Healthcare Conference to ... Grand Hyatt Hotel in New York City ... at 11:40 a.m. Eastern time on Friday, September 18, ... accessed at Luminex Corporation,s website at http://www.luminexcorp.com . ...
(Date:9/4/2015)... 4, 2015 According to a ... Plateletpheresis, Erythrocytapheresis, Leukapheresis, and Photopheresis) by Procedure (Therapeutic Apheresis, ... - Global Forecast to 2020", published by MarketsandMarkets, the ... Billion by 2020, growing at a CAGR of 11.2% ... Browse 139 Tables and 45 F ...
(Date:9/4/2015)... Oramed Pharmaceuticals Inc. (NASDAQ: ... focused on the development of oral drug delivery systems, ... upcoming Rodman & Renshaw 17 th Annual Global ... New York City .  Dr. Michael ... overview on September 9, 2015. Presentation ...
Breaking Medicine Technology:Luminex Corporation To Present At The Morgan Stanley Global Healthcare Conference 2Apheresis Market Worth 2.5 Billion USD by 2020 2Apheresis Market Worth 2.5 Billion USD by 2020 3Apheresis Market Worth 2.5 Billion USD by 2020 4Apheresis Market Worth 2.5 Billion USD by 2020 5Oramed to Present at the Rodman & Renshaw Global Investment Conference 2Oramed to Present at the Rodman & Renshaw Global Investment Conference 3
... 2011 Par Pharmaceutical Companies, Inc. (NYSE: PRX ... EST on Friday, January 6, 2012 at the Millennium Hotel, ... Executive Officer, Patrick G. LePore, and other members of the ... growth strategy, current products and pipelines, and business outlook to ...
... Calif., Dec. 5, 2011  Beyond Lucid Technologies, Inc., ... disaster management, and First Response industries, today announced ... the mHealth Summit, and the publication of a ... connect ambulances with hospitals via telemedicine. ...
Cached Medicine Technology:Beyond Lucid Technologies Advances Telemedicine for EMS Providers 2Beyond Lucid Technologies Advances Telemedicine for EMS Providers 3
(Date:9/4/2015)... ... ... Keeping mold top of mind is important when considering indoor air quality, ... anywhere - on carpet, clothing, food, paper, and even in places you can’t see, ... home is key to preventing mold growth, which if exposed to can lead to ...
(Date:9/4/2015)... ... ... Many consumers are looking for a quick and convenient way to produce a hot remedy ... Cups provide a quick and simple way to brew a hot cup of cold remedy ... a result, they enhance comfort and health. The invention features a novel design that is ...
(Date:9/4/2015)... (PRWEB) , ... September 04, 2015 , ... Having access ... This has led to an increasing amount of unnecessary emergency room visits which affects ... and taxes the country’s health bill. Fortunately, a solution to alleviate this problem has ...
(Date:9/4/2015)... ... September 04, 2015 , ... Compliance ... to settlements under the Stark physician self-referral law. “Stark Law DOs and ... from Atlantic Information Services, Inc. (AIS), will detail which deals are attracting the ...
(Date:9/4/2015)... ... 2015 , ... Friday night, Chicago lovebirds Jenny McCarthy and Donnie Wahlberg celebrated ... event supporting families affected by autism, raising nearly $250,000. , 150 guests, including ... the Oscar Swan Inn to support the cause. , McCarthy tugged the heartstrings ...
Breaking Medicine News(10 mins):Health News:September is Mold Awareness Month 2Health News:September is Mold Awareness Month 3Health News:September is Mold Awareness Month 4Health News:Redesigned Packaging for Powdered Medicinal Mix Invented by InventHelp® Client (CBA-2637) 2Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 2Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 3Health News:Sept. 17 Webinar to Offer Best Practices for Physician Contracts 2Health News:Jenny McCarthy & Donnie Wahlberg Help Raise Over $200,000 For Generation Rescue’s ‘Night Of Hope’ Chicago Charity Event 2
... -- Researchers from Duke University, the University of Cincinnati ... hoping to find a geographical pattern to help explain ... disease amyotrophic lateral sclerosis (ALS) at twice the normal ... layering military records of troop locations onto Gulf-area maps, ...
... in Progressive Inflammatory brain Disease) study at the Peninsula Medical ... news that the full cohort of 493 people with multiple ... is a clinical trial which will evaluate whether tetrahydrocannabinol (THC), ... plant (and the main active ingredient) is able to slow ...
... the only ones who need to be concerned about ... may trigger serious cardiovascular problems for some spectators. ... at Northwestern University,s Feinberg School of Medicine warn that ... of pollution can cause heart attacks and strokes within ...
... N.H., July 21 iCAD, Inc. (Nasdaq:,ICAD), an ... the completion of its previously announced,agreement to purchase ... technology company based in White Plains, NY. The,purchase ... in cash and,1,086,957 shares of iCAD common stock. ...
... Experienced a 15 Percent Increase in Prescription ... Report from HealthLeaders-InterStudy, NASHVILLE, Tenn., July ... care market intelligence, reports that Excellus,BlueCross BlueShield ... pharmacy programs and public education efforts. According ...
... Ala., July 21 Health,Care Systems, Inc. (HCS), ... market leader in medication reconciliation solutions, has entered,into ... the largest,locally owned not-for-profit hospitals in the nation ... as a teaching facility for The,University of Alabama ...
Cached Medicine News:Health News:Researchers probe geographical ties to ALS cases among 1991 Gulf War veterans 2Health News:Researchers probe geographical ties to ALS cases among 1991 Gulf War veterans 3Health News:Milestone for cannabinoid MS study 2Health News:Beijing pollution may trigger heart attacks, strokes 2Health News:iCAD Completes Acquisition of CAD Sciences 2Health News:New York's Excellus BlueCross BlueShield to Continue Generic Medication Promotion to Help Control Costs 2Health News:Huntsville Hospital Signs With Health Care Systems, Inc. for Automated Medication Reconciliation Services 2
... technologies - Quantum™ LEAP® balloon material ... unite in the Quantum™ Maverick® Balloon ... force balloon with exceptional deliverability. Easier ... shaft technology improves trackability and crossability ...
... Finnpipette Focus multichannel ... dispensing of reagents into ... for 0.1-10 l volumes. ... of Finnpipette Focus multichannels, ...
... in mind, Pipetman Ultra Multichannel is ... PCR* sequencing, immunology assays, series dispensing ... Diamond Tips from Gilson's patented Rocky ... performance and assure productivity.,* PCR process ...
... wide variety of applications. • Whole pipette is ... freely rotated against the handle to work in ... angle towards the microtiter plate. • The special ... common pipette tips, and provides a firm, parallel ...
Medicine Products: